SG11201400145VA - Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide - Google Patents
Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamideInfo
- Publication number
- SG11201400145VA SG11201400145VA SG11201400145VA SG11201400145VA SG11201400145VA SG 11201400145V A SG11201400145V A SG 11201400145VA SG 11201400145V A SG11201400145V A SG 11201400145VA SG 11201400145V A SG11201400145V A SG 11201400145VA SG 11201400145V A SG11201400145V A SG 11201400145VA
- Authority
- SG
- Singapore
- Prior art keywords
- ylsulfanyl
- indazol
- benzamide
- pyridin
- vinyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541525P | 2011-09-30 | 2011-09-30 | |
| PCT/IB2012/055126 WO2013046133A1 (en) | 2011-09-30 | 2012-09-26 | Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201400145VA true SG11201400145VA (en) | 2014-03-28 |
Family
ID=47116146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201400145VA SG11201400145VA (en) | 2011-09-30 | 2012-09-26 | Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20140248347A1 (en) |
| EP (1) | EP2760434A1 (en) |
| JP (1) | JP2013079234A (en) |
| KR (1) | KR20140069297A (en) |
| CN (1) | CN103826618A (en) |
| AR (1) | AR088195A1 (en) |
| AU (1) | AU2012313885A1 (en) |
| BR (1) | BR112014007163A2 (en) |
| CA (1) | CA2847860A1 (en) |
| IL (1) | IL231437A0 (en) |
| MX (1) | MX2014003886A (en) |
| RU (1) | RU2014107767A (en) |
| SG (1) | SG11201400145VA (en) |
| TW (2) | TW201328725A (en) |
| WO (1) | WO2013046133A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2682859C (en) † | 2007-04-05 | 2013-10-08 | Pfizer Products Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl)indazole for treatment of abnormal cell growth in mammals |
| WO2013068909A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
| ES2813877T3 (en) | 2013-08-28 | 2021-03-25 | Crown Bioscience Inc Taicang | Gene expression flags predictive of a subject's response to a multikinase inhibitor and methods of using the same |
| WO2015067224A1 (en) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole |
| EP3971209A1 (en) | 2014-02-04 | 2022-03-23 | Pfizer Inc. | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
| CN104013589A (en) * | 2014-05-07 | 2014-09-03 | 万特制药(海南)有限公司 | Axitinib orally disintegrating tablet and preparation method thereof |
| US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| CN105769785B (en) * | 2014-12-26 | 2019-02-01 | 四川科伦药物研究院有限公司 | A kind of preparation method of pazopanib tablet |
| WO2016108106A1 (en) * | 2014-12-29 | 2016-07-07 | Shilpa Medicare Limited | An improved process for preparation of axitinib |
| WO2016137985A1 (en) | 2015-02-26 | 2016-09-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| MX2017016324A (en) | 2015-06-16 | 2018-03-02 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments. |
| CN106913547B (en) * | 2015-12-28 | 2021-09-14 | 山东新时代药业有限公司 | Acixtinib tablet and preparation method thereof |
| AU2017339856A1 (en) | 2016-10-06 | 2019-05-23 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| CN106918658B (en) * | 2017-01-22 | 2020-01-31 | 合肥拓锐生物科技有限公司 | axitinib raw materials and analysis method of related substances in preparation thereof |
| CN109928964B (en) * | 2017-12-18 | 2022-04-15 | 江苏开元药业有限公司 | Synthetic method of axitinib intermediate |
| WO2019234581A1 (en) * | 2018-06-04 | 2019-12-12 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions of axitinib |
| WO2020003196A1 (en) * | 2018-06-28 | 2020-01-02 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of axitinib |
| US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
| EP3965743A1 (en) * | 2019-05-09 | 2022-03-16 | Synthon B.V. | Pharmaceutical composition comprising axitinib |
| CN112999176B (en) * | 2019-12-19 | 2022-09-13 | 鲁南制药集团股份有限公司 | Acertinib tablet |
| CN113943271B (en) * | 2020-07-15 | 2023-11-14 | 鲁南制药集团股份有限公司 | Acetinib crystal form and preparation method thereof |
| WO2023166420A1 (en) | 2022-03-03 | 2023-09-07 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| EP4282415A1 (en) | 2022-05-26 | 2023-11-29 | Genepharm S.A. | A stable tablet composition of axitinib |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| BRPI0409230A (en) | 2003-04-03 | 2006-03-28 | Pfizer | dosage forms comprising ag013736 |
| EP1809621A1 (en) | 2004-11-02 | 2007-07-25 | Pfizer, Inc. | Methods of preparing indazole compounds |
| MX2007005273A (en) | 2004-11-02 | 2007-07-19 | Pfizer | Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2 -(pyridin-2-yl)ethenyl]indazole. |
| CN101052633A (en) | 2004-11-02 | 2007-10-10 | 辉瑞大药厂 | Methods of preparing indazole compounds |
| CN101094836A (en) | 2004-11-02 | 2007-12-26 | 辉瑞大药厂 | Methods for preparing indazole compounds |
| CN101044138A (en) | 2004-11-02 | 2007-09-26 | 辉瑞有限公司 | Methods for preparing indazole compounds |
| JP2008540629A (en) | 2005-05-19 | 2008-11-20 | ファイザー・インク | Pharmaceutical composition comprising amorphous VEGF-R inhibitor |
| CA2682859C (en) * | 2007-04-05 | 2013-10-08 | Pfizer Products Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl)indazole for treatment of abnormal cell growth in mammals |
-
2012
- 2012-09-26 AU AU2012313885A patent/AU2012313885A1/en not_active Abandoned
- 2012-09-26 EP EP12780293.2A patent/EP2760434A1/en not_active Withdrawn
- 2012-09-26 TW TW101135312A patent/TW201328725A/en unknown
- 2012-09-26 SG SG11201400145VA patent/SG11201400145VA/en unknown
- 2012-09-26 US US14/348,415 patent/US20140248347A1/en not_active Abandoned
- 2012-09-26 WO PCT/IB2012/055126 patent/WO2013046133A1/en active Application Filing
- 2012-09-26 CA CA2847860A patent/CA2847860A1/en not_active Abandoned
- 2012-09-26 BR BR112014007163A patent/BR112014007163A2/en not_active IP Right Cessation
- 2012-09-26 MX MX2014003886A patent/MX2014003886A/en unknown
- 2012-09-26 CN CN201280047467.0A patent/CN103826618A/en active Pending
- 2012-09-26 TW TW104115016A patent/TW201531309A/en unknown
- 2012-09-26 RU RU2014107767/04A patent/RU2014107767A/en not_active Application Discontinuation
- 2012-09-26 KR KR1020147011350A patent/KR20140069297A/en not_active Application Discontinuation
- 2012-09-27 JP JP2012213422A patent/JP2013079234A/en not_active Withdrawn
- 2012-09-28 AR ARP120103631A patent/AR088195A1/en unknown
-
2014
- 2014-03-10 IL IL231437A patent/IL231437A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013046133A1 (en) | 2013-04-04 |
| CA2847860A1 (en) | 2013-04-04 |
| AU2012313885A1 (en) | 2014-03-13 |
| MX2014003886A (en) | 2014-05-13 |
| AR088195A1 (en) | 2014-05-14 |
| TW201328725A (en) | 2013-07-16 |
| BR112014007163A2 (en) | 2017-04-04 |
| US20140248347A1 (en) | 2014-09-04 |
| TW201531309A (en) | 2015-08-16 |
| IL231437A0 (en) | 2014-04-30 |
| RU2014107767A (en) | 2015-11-10 |
| EP2760434A1 (en) | 2014-08-06 |
| CN103826618A (en) | 2014-05-28 |
| KR20140069297A (en) | 2014-06-09 |
| JP2013079234A (en) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201400145VA (en) | Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide | |
| IL276012A (en) | Pharmaceutical compositions comprising sorbitan esters | |
| IL230010B (en) | Inhalable pharmaceutical compositions | |
| GB201113662D0 (en) | Pharmaceutical compositions | |
| ZA201308208B (en) | Pharmaceutical compositions | |
| HK1199824A1 (en) | Pharmaceutical compositions | |
| EP2661273A4 (en) | Pharmaceutical compositions of iron for oral administration | |
| EP2731605A4 (en) | Pharmaceutical compositions for rectal administration | |
| HRP20180567T1 (en) | Pharmaceutical composition of omeprazole | |
| PL2766008T3 (en) | Compositions for nasal application of improved stability | |
| ZA201306734B (en) | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor | |
| GB201118181D0 (en) | Pharmaceutical compositions | |
| ZA201402166B (en) | Compositions of efavirenz | |
| ZA201402165B (en) | Compositions of lopinavir | |
| IL229417A0 (en) | Pharmaceutical composition comprising fexofenadine | |
| PL2696846T3 (en) | Oral pharmaceutical dispersion compositions | |
| GB201100786D0 (en) | Pharmaceutical compositions of immunosuppressants | |
| EP2714715A4 (en) | Pharmaceutical compositions | |
| GB201407689D0 (en) | Pharmaceutical compositions of antihypertensives | |
| ZA201205978B (en) | Solid pharmaceutical composition for buccal administration of agomelatine | |
| SG11201401570YA (en) | Pharmaceutical compositions of resveratrol | |
| GB201105224D0 (en) | Novel pharmaceutical compositions | |
| EP2727594A4 (en) | Novel pharmaceutical composition | |
| HUP1100561A2 (en) | Cocrystals for producing pharmaceutical compositions |